Drug Profile
EC 0225
Alternative Names: DAVLBH and mitomycin-C conjugate; Desacetylvinblastine hydrazide and mitomycin-C conjugate; EC0225Latest Information Update: 31 Dec 2018
Price :
$50
*
At a glance
- Originator Endocyte
- Class Antineoplastics; Drug conjugates; Vinca alkaloids
- Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Microtubule protein inhibitors; Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 21 Dec 2018 Endocyte has been acquired by Novartis
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease) in USA (IV, Injection)
- 01 Nov 2010 Endocyte completes a phase I trial in metastatic Cancer in USA